ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2614

Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Abstract Number: 2615

The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Abstract Number: 2616

Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Abstract Number: 2617

Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration
Abstract Number: 2618

Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers
Abstract Number: 2619

What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Abstract Number: 2620

Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System
Abstract Number: 2621

Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
Abstract Number: 2622

Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Abstract Number: 2623

Disease Activity is a Novel Imaging Biomarker Associated with Knee Pain: Data from the Osteoarthritis Initiative
Abstract Number: 2624

Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee
Abstract Number: 2625

Early Detection of Knee Osteoarthritis – The Role of a Composite Disease Activity Metric: Data from the Osteoarthritis Initiative
Abstract Number: 2626

Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Abstract Number: 2627

Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
Abstract Number: 2628

Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].